CRM Investigational Product Management 2

Question 1

What is a Certificate of Analysis (CoA) used for in the context of investigational product management?

Accepted Answer

To confirm the identity, purity, potency, and quality of the investigational product

Answer

To document subject consent for experimental treatment

Answer

To record adverse events related to the product

Answer

To authorize shipment of product across international borders

Question 2

At the end of a clinical trial, investigational product that has not been dispensed must typically be:

Accepted Answer

Returned to the sponsor or destroyed per protocol and documented

Answer

Kept at the site indefinitely

Answer

Given to site staff for personal use

Answer

Donated to a local pharmacy

Question 3

What is 'blinding' in the context of investigational product management?

Accepted Answer

A process to conceal the allocation of treatment so subjects or investigators are unaware of treatment assignment

Answer

A method to protect IP from light exposure

Answer

A regulatory requirement for labeling IP in foreign languages

Answer

A system for encrypting electronic drug dispensing records

Question 4

Which of the following is required on the label of an investigational product shipped to a U.S. clinical trial site?

Accepted Answer

A statement such as 'Caution: New Drug — Limited by Federal Law to Investigational Use'

Answer

The subject's full name and date of birth

Answer

The sponsor's quarterly revenue figures

Answer

A list of all enrolled trial subjects

Question 5

A randomization schedule in a blinded clinical trial is considered a form of:

Accepted Answer

Essential document to be filed in the Trial Master File

Answer

Adverse event documentation

Answer

Optional administrative record

Answer

Subject recruitment material

Question 6

What is the purpose of an unblinding procedure in a clinical trial?

Accepted Answer

To reveal a specific subject's treatment assignment in emergency medical situations

Answer

To permanently reveal all treatment assignments to investigators at interim analysis

Answer

To allow sponsors to change the randomization scheme mid-trial

Answer

To disclose proprietary formulation information to site staff

Question 7

Which practice best ensures proper investigational product chain of custody during shipment from sponsor to site?

Accepted Answer

Completion of shipping manifests, temperature monitoring logs, and signed receipts

Answer

Verbal confirmation between the shipping carrier and site staff

Answer

Email notification from the sponsor only

Answer

A single photograph of the package upon arrival